Commission Regulation (EC) No 17/97 of 8 January 1997 amending Annexes I, II, III and IV of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin
Date: 1997-01-08
Institutions: European Commission
Subjects: animal product, food inspection, health control, veterinary drug, waste








L_1997005EN.01001201.xml










9.1.1997   


EN


Official Journal of the European Communities


L 5/12





COMMISSION REGULATION (EC) No 17/97
of 8 January 1997
amending Annexes I, II, III and IV of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), as last amended by Commission Regulation (EC) No 2034/96 (2) and in particular Articles 6, 7 and 8 thereof,
Whereas, in accordance with Regulation (EEC) No 2377/90, maximum residue limits must be established progressively for all pharmacologically active substances which are used within the Community in veterinary medicinal products intended for administration to food-producing animals;
Whereas maximum residue limits should be established only after the examination within the Committee for Veterinary Medicinal Products of all the relevant information concerning the safety of residues of the substance concerned for the consumer of foodstuffs of animal origin and the impact of residues on the industrial processing of foodstuffs;
Whereas, in establishing maximum residue limits for residues of veterinary medicinal products in foodstuffs of animal origin, it is necessary to specify the animal species in which residues may be present, the levels which may be present in each of the relevant meat tissues obtained from the treated animal (target tissue) and the nature of the residue which is relevant for the monitoring of residues (marker residue);
Whereas, for the control of residues, as provided for in appropriate Community legislation, maximum residue limits should usually be established for the target tissues of liver or kidney; whereas, however, the liver and kidney are frequently removed from carcasses moving in international trade, and maximum residue limits should therefore also always be established for muscle or fat tissues;
Whereas, in the case of veterinary medicinal products intended for use in laying birds, lactating animals or honey bees, maximum residue limits must also be established for eggs, milk or honey;
Whereas, eprinomectin should be inserted into Annex I to Regulation (EEC) No 2377/90;
Whereas zinc acetate, zinc chloride, zinc gluconate, zinc oleate, zinc stearate, chlorhexidine, glycerol formal, hesperidin, hesperidin methyl chalcone, menbutone and quatresin should be inserted into Annex II to Regulation (EEC) No 2377/90;
Whereas, in order to allow for the completion of scientific studies, flumequine, doxycycline and albendazole sulfoxide should be inserted into Annex III to Regulation (EEC) No 2377/90;
Whereas it appears that maximum residue limits cannot be established for chlorpromazine because residues, at whatever limit, in foodstuffs of animal origin constitute a hazard to the health of the consumer, whereas chlorpromazine should therefore be inserted into Annex IV to Regulation (EEC) No 2377/90;
Whereas a period of 60 days should be allowed before the entry into force of this Regulation in order to allow Member States to make any adjustment which may be necessary to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Council Directive 81/851/EEC (3), as last amended by Directive 93/40/EEC (4) to take account of the provisions of this Regulation;
Whereas the measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,
HAS ADOPTED THIS REGULATION:
Article 1
Annexes I, II, III and IV of Regulation (EEC) No 2377/90 are hereby amended as set out in the Annex hereto.
Article 2
This Regulation shall enter into force on the sixtieth day following its publication in the Official Journal of the European Communities.

This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 8 January 1997.


For the Commission

Martin BANGEMANN

Member of the Commission





(1)  OJ No L 224, 18. 8. 1990, p. 1.

(2)  OJ No L 272, 25. 10. 1996, p. 2.

(3)  OJ No L 317, 6. 11. 1981, p. 1.

(4)  OJ No L 214, 24. 8. 1993, p. 31.


ANNEX
Regulation (EEC) No 2377/90 is modified as follows:






A.


Annex I is modified as follows:






2.


Anti-parasitic agents






2.3.


Agents acting against endo- and ectoparasites






2.3.1.


Avermectins










Pharmacologically active substance


Marker residue


Animal Species


MRLs


Target tissues


Other provisions










‘2.3.1.4.


Eprinomectin






Eprinomectin B1a


Bovine


30 μg/kg


Muscle


 




30 μg/kg


Fat




600 μg/kg


Liver




100 μg/kg


Kidney




30 μg/kg


Milk’


























B.


Annex II is modified as follows:






1.


Inorganic chemicals







Pharmacologically active substance(s)


Animal Species


Other provisions










‘1.24.


Zinc acetate






All food producing species


 










1.25.


Zinc chloride






All food producing species


 










1.26.


Zinc gluconate






All food producing species


 










1.27.


Zinc oleate






All food producing species


 










1.28.


Zinc stearate






All food producing species’


 














2.


Organic compounds







Pharmacologically active substance(s)


Animal Species


Other provisions










‘2.69.


Chlorhexidine






All food producing species


For topical use only










2.70.


Glycerol formal






All food producing species


 










2.71.


Hesperidin






Equidae


 










2.72.


Hesperidin methyl chalcone






Equidae


 










2.73.


Menbutone






Bovine, ovine, caprine, porcine, equidae


 










2.74.


Quatresin






All food producing species


For use as preservative only at concentrations of up to 0,5 %’


















C.


Annex III is modified as follows:






1.


Anti-infectious agents






1.2.


Antibiotics






1.2.6.


Quinolones










Pharmacologically active substance


Marker residue


Animal Species


MRLs


Target tissues


Other provisions










‘1.2.6.4.


Flumequine






Flumequine


Bovine, ovine, porcine, chicken


50 μg/kg


Muscle, fat or fat/skin


Provisional MRLs expire on 1.1.2000’




100 μg/kg


Liver




300 μg/kg


Kidney




Salmonidae


150 μg/kg


Muscle/skin










1.2.8.


Tetracyclines










Pharmacologically active substance


Marker residue


Animal Species


MRLs


Target tissues


Other provisions










‘1.2.8.1.


Doxycycline






Sum of parent drug and its 4-epimer


Porcine, poultry


600 μg/kg


Kidney


Provisional MRLs expire on 1.1.1998’




300 μg/kg


Liver, skin/fat




100 μg/kg


Muscle




Bovine


600 μg/kg


Kidney




300 μg/kg


Liver




100 μg/kg


Muscle


























2.


Antiparasitic agents






2.1.


Agents acting against endoparasites






2.1.1.


Benzimidazoles and pro-benzimidazoles










Pharmacologically active substance


Marker residue


Animal Species


MRLs


Target tissues


Other provisions










‘2.1.1.10.


Albendazole sulphoxide






Sum of albendazole, albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole


Bovine, ovine, pheasant


1 000 μg/kg


Liver


Provisional MRLs expire on 1.1.1998’




500 μg/kg


Kidney




100 μg/kg


Muscle, fat




Bovine, ovine


100 μg/kg


Milk


























D.


Annex IV is modified as follows:
List of pharmacologically active substances for which no maximum levels can be fixed:






‘8.


Chlorpromazine’